Liabilities / Assets
83rd percentile
Higher debt load relative to assets than 83% of similar nonprofits.
Neuroendocrine Tumor Research Foundation
990 • Fiscal year 2013 • EIN 20-1945347
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.66x
Liabilities / Revenue
81st percentile
Higher debt load relative to revenue than 81% of similar nonprofits.
Net Margin
71st percentile
Higher net margin than 71% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
90th percentile
Faster asset growth than 90% of similar nonprofits.
Revenue Growth
28th percentile
Faster revenue growth than 28% of similar nonprofits.
Balance Sheet
Assets
Up$2,675,315
Up $749,950 (+39%) from 2012
Net Assets
Up$902,372
Up $301,812 (+50%) from 2012
Liabilities
Up$1,772,943
Up $448,138 (+34%) from 2012
Revenue And Expenses
Revenue
Down$2,271,318
Down $120,369 (-5.0%) from 2012
Expenses
Down$1,969,506
Down $71,620 (-3.5%) from 2012
Net Income
Down$301,812
Down $48,749 (-14%) from 2012
Historical Trend
Filing Detail Status
This 2013 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2013 to Dec 31, 2013
Mission and Program Overview
Mission
To fund research to discover cures & more effective treatments for neuroendocrine cancers. The NET Research Foundation is committed to improving the lives of those affected by neuroendocrine cancer by providing information & educational resources.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2013 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $2,675,315
- Liabilities
- $1,772,943
- Net assets
- $902,372
- Revenue
- $2,271,318
- Expenses
- $1,969,506
- Net income
- $301,812